We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Reaction Biology Awarded NIH SBIR Grant

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Reaction Biology Corporation ("RBC") has announced that it has been awarded an SBIR grant from the National Cancer Institute to create a kinase profiling and high throughput screening method using radioisotopes and microarrays. 

The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC’s DiscoveryDot™ nanoliter screening platform. 

While screening kinase activity with radioisotope detection is considered by many in the drug-discovery industry to be the "gold standard" of kinase assays, use of the format is limited by expense and the difficulty of radioactive disposal. 

The DiscoveryDot™ platform uses only a fraction of the reagents compared to well plate methods. 

"Due to our nano-scale format, the amount of radioisotope used in the process should be minimal," said RBC Chief Technology Officer Haiching Ma, Ph.D. 

"This should lead to far fewer disposal and handling problems, and reduced cost overall."